Study the effects of sorafenib in TGF-β signaling
碩士 === 國立中山大學 === 生物科學系研究所 === 106 === The multi-kinase inhibitor sorafenib is the FDA approved drug for the treatment of advanced hepatocellular carcinoma (HCC) and other solid tumors. Previous studies have showed that Transforming Growth Factor-β (TGF-β) signaling may help tumor progression in HCC...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | zh-TW |
| Published: |
2018
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/4jjrv6 |